131I标记索拉非尼纳米脂质体的制备及其对未分化型甲状腺癌的疗效研究

Study on Preparation of 131I Labeled Sorafenib Nanoliposomes and Its Effect on Anaplastic Thyroid Carcinoma

关键词:  未分化型甲状腺癌  索拉非尼  纳米载体

Key words:  anaplastic thyroid carcinoma  sorafenib  nanocarriers

摘要:

目的 观察¹³¹I-牛血清白蛋白（BSA）-聚己内酯（PCL）-索拉非尼（sorafenib）在人甲状腺未分化肿瘤细胞8305C荷瘤裸鼠体内的靶向性分布及其抑瘤作用。方法 制备并鉴定BSA-PCL-sorafenib、¹³¹I-BSA-PCL-sorafenib脂质体。12只裸鼠接种人甲状腺未分化肿瘤细胞8305C建立模型，造模成功后分别尾静脉注射生理盐水（对照组）、¹³¹I、BSA-PCL-sorafenib和¹³¹I-BSA-PCL-sorafenib，通过SPECT/CT显像观察注射后不同时间荷瘤裸鼠体内的放射性分布，比较各组荷瘤裸鼠的体质量及肿瘤质量和体积变化。结果 温育60 min后，¹³¹I-BSA-PCL-sorafenib组细胞荧光强度高于对照组。注射22 d后，¹³¹I-BSA-PCL-sorafenib组的肿瘤质量和体积最小。结论 ¹³¹I-BSA-PCL-sorafenib可有效抑制8305C细胞造模诱发的肿瘤生长，在未分化型甲状腺癌的治疗和预后评估中有良好的应用前景。

Abstract:

OBJECTIVE To observe the radioactivity distribution and antitumor efficacy of ¹³¹I-bovine serum albumin (BSA)-polycaprolactone(PCL)-sorafenib in human anaplastic thyroid carcinoma cells 8305C-bearing nude mouse model. METHODS Prepared and identified BSA-PCL-sorafenib, ¹³¹I-BSA-PCL-sorafenib liposomes. Twelve nude mice were inoculated with human anaplastic thyroid carcinoma cells 8305C to establish model. After successful modeling, normal saline (control group), ¹³¹I, BSA-PCL-sorafenib, and ¹³¹I-BSA-PCL-sorafenib were injected into the tail vein. The radioactivity distribution in tumor-bearing nude mice at different times after injection was observed by SPECT/CT imaging, and the body weight and tumor mass and volume changes of tumor-bearing nude mice in each group were compared. RESULTS After incubation for 60 min, the fluorescence intensity in ¹³¹I-BSA-PCL-sorafenib group was higher than that in control group. After injection for 22 d, the weight and volume of tumor in ¹³¹I-BSA-PCL-sorafenib group was the smallest one in four groups. CONCLUSION ¹³¹I-BSA-PCL-sorafenib can effectively inhibit the tumor growth of 8350C induced-mouse tumor model, which gives a good suggestion for the treatment and prognosis evaluation of anaplastic thyroid carcinoma.